BRISTOL-MYERS SQUIBB COMPANY SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense of $14.09 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Valuation and Qualifying Accounts
us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2025 was $14.09B, a 21.97% increase from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2024 was $11.55B, a 26.13% increase from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2023 was $9.16B, a 22.50% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY sec schedule, 12-09, valuation allowances and reserves, additions, charge to cost and expense for fiscal 2022 was $7.48B, a 3.02% increase from fiscal 2021.
| Period end | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month | SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense 12 month as first filed |
|---|---|---|
| 2025-12-31 | $14.09B 10-K · filed 2026-02-11 | |
| 2024-12-31 | $11.55B 10-K · filed 2026-02-11 | |
| 2023-12-31 | $9.16B 10-K · filed 2026-02-11 | |
| 2022-12-31 | $7.48B 10-K · filed 2025-02-12 | |
| 2021-12-31 | $7.26B 10-K · filed 2024-02-13 | |
| 2020-12-31 | $5.84B 10-K · filed 2023-02-14 | |
| 2019-12-31 | $3.69B 10-K · filed 2022-02-09 | $3.73B 10-K · filed 2020-02-24 |
| 2018-12-31 | $2.74B 10-K · filed 2021-02-10 | |
| 2017-12-31 | $2.09B 10-K · filed 2020-02-24 | |
| 2016-12-31 | $1.61B 10-K · filed 2019-02-25 | |
| 2015-12-31 | $1.06B 10-K · filed 2018-02-13 | |
| 2014-12-31 | $773.00M 10-K · filed 2017-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |